MURA Company Profile and Key Details

MURA has shown mixed momentum, gaining 0.99% over the past week and -1.45% over the past quarter, though year-to-date performance is down -36.65%. Short-term trend indicators are bullishly aligned (SMA20 -1.6%, SMA50 -1.93%, SMA200 -13.76%). The stock’s 14-day RSI is 40.09 (neutral), while the ATR of 0.02 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -56.96% below its high and over 114.74% above its low.

Mural Oncology plc has 17.32 million shares outstanding. The public float is 14.04 million shares, elevated short interest at 1.20% of float. This equals 207.27 thousand shares. The short ratio is 0.85 days. Institutional investors hold 66.19% of the float. Insiders own 13.03%. Loew Caroline holds 293.06 thousand shares, Cutler Adam D. has 99.29 thousand shares and Goodman Vicki L has 84.73 thousand shares.

Mural Oncology plc earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -64.41%. The prior quarter beat by 56.64%. Over the last six quarters, Apple has recorded several small beats. These include -1.84% in August 13, 2024.

Mural Oncology plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.34. This means the shares are trading below this model’s fair value.

The stock is currently mid-range between its 52-week high and low $0.95 and $4.74. With a market capitalization of about $35.38 million, Mural Oncology plc is classified as a micro-cap and shows higher-than-market volatility (beta ~2.96). Key stats such as the average daily volume over the past year has been around 170.82 thousand shares, in line with its 52-week average. Headquartered in Dublin, None, Mural Oncology plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Caroline J. Loew, the company employs approximately 116 people and listed since November 16, 2023. Mural Oncology Plc, a clinical-stage company, is dedicated to discovering and advancing immune-based therapies for individuals battling cancer.

Our AI price prediction model suggests that Mural Oncology plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.9%, with price expected at $1.94 by December 18, 2025, within a range of $1.92 to $1.97 3-Month Outlook: Projected fall of -80.39%, reaching $0.40 by March 04, 2026, with a range of $0.23 to $0.48. 1-Year Outlook: Projected gain of 27.94%, with price at $2.61 by December 04, 2026, within a range of $1.70 to $2.86.

Mural Oncology plc (NASDAQ:MURA) shares are down -36.65% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Mural Oncology plc trading at a premium to the broader market with a P/E of -0.41. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $15.14, suggesting 642.16% upside. Our AI forecast model points to short-term weakness (-4.9% over two weeks), a medium-term fall (-80.39% over three months), and a longer-term gain (27.94% over one year), with expected trading ranges indicating moderate volatility.

Mural Oncology plc trades at a P/E ratio of -0.41, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.64 suggesting the stock is closer to book value. The P/FCF stands at -0.41, also above market averages.